SWI4 Antibody

What is the recommended protocol for validating SWI4 antibody specificity?

SWI4 antibody validation should include multiple controls to ensure specificity:

Recommended validation protocol:

• Compare immunostaining patterns between wild-type and swi4Δ deletion strains

• Perform western blot analysis with both strains to confirm absence of band in deletion strain

• Use affinity purification followed by preadsorption with fixed yeast cells to improve specificity

Critical step: Preadsorb antibody to a 1:1 mixture of fixed yeast cells and spheroplasts from swi4Δ strain to reduce background .

Researchers from University College London successfully validated SWI4 polyclonal antibodies by demonstrating lack of nuclear signal in swi4Δ cells while wild-type cells showed clear nuclear localization during G1 phase .

How should SWI4 antibodies be prepared for immunofluorescence studies?

Effective immunofluorescence with SWI4 antibodies requires careful preparation:

• Affinity purify polyclonal SWI4 antibody

• Preadsorb with fixed yeast cells (3.7% formaldehyde fixation for 1h at 30°C)

• Prepare cells as spheroplasts using β-mercaptoethanol (0.1%) and Zymolyase 20000T (0.25 mg/ml)

• Use multiple preadsorption cycles (7-8 rounds including overnight incubation)

This preparation method significantly reduces background signal and has been validated in studies examining SWI4 localization across cell cycle phases .

What fixation methods are most effective for SWI4 immunofluorescence?

Optimal fixation depends on the experimental goals:

For standard immunofluorescence:

• Fix cells in 3.6-3.7% formaldehyde at 30°C for 1-2 hours

• Wash twice with phosphate buffer (100 mM KH₂PO₄, pH 7.4 or PBS with 1.2M sorbitol)

• Prepare spheroplasts using β-mercaptoethanol (0.1%) and Zymolyase 20000T (0.25 mg/ml)

For ChIP applications:

• Cross-link samples in 1% formaldehyde overnight on ice

• Process samples according to standard ChIP protocols

Research indicates that insufficient fixation leads to loss of nuclear SWI4 signal, while excessive fixation can mask epitopes.

How can SWI4 antibodies be used to study cell cycle progression?

SWI4 antibodies are valuable tools for cell cycle analysis:

Applications in cell cycle research:

• Immunofluorescence to track SWI4 nuclear localization during G1/S transition

• ChIP assays to monitor SWI4 binding to target promoters throughout the cycle

• Quantitative protein measurements using scanning number and brightness microscopy

Key findings: Studies have shown that SWI4 nuclear localization is cell cycle-regulated, with highest nuclear accumulation during late G1 phase. Both protein level and nuclear/cytoplasmic distribution change throughout the cycle .

These patterns have been confirmed through synchronized cell cultures using various arrest methods .

What is the relationship between SWI4 protein levels and cell size at Start?

Recent research has established a quantitative relationship between SWI4 accumulation and cell size control:

Key findings:

• SWI4 protein accumulates linearly with cell size in G1 phase

• Approximately 190 SWI4 molecules represent a threshold level for triggering Start

• Mutation of SBF binding sites in the SWI4 promoter reduces the rate of SWI4 accumulation by 33-50%

• A threshold model with SWI4 titrating SBF binding sites accurately predicts cell size effects under different genetic and nutritional conditions

SWI4 accumulation rates under different conditions:

This quantitative framework helps explain how SWI4 contributes to cell size control .

How do you interpret changes in SWI4 binding patterns during cell cycle progression?

Changes in SWI4 binding must be carefully analyzed within the context of the cell cycle:

Interpretation guidelines:

• Use synchronization methods with minimal impact on transcription (e.g., centrifugal elutriation)

• Normalize ChIP signals to appropriate controls (e.g., non-specific IgG, intergenic regions)

• Consider the influence of Whi5 repressor binding and phosphorylation status

• Account for potential Swi6-independent binding at some promoters

Research findings: ChIP assays have shown that SWI4 binding to CLN2 promoter peaks during G1 phase and rapidly decreases after Start. Without Swi6, protection of SCBs cannot be detected by in vivo footprinting, indicating that SWI4 alone typically cannot bind DNA in vivo .

How can I distinguish between SBF (Swi4-Swi6) and MBF (Mbp1-Swi6) binding in genomic studies?

Distinguishing between these related complexes requires specific approaches:

Recommended methods:

• Use specific antibodies against the DNA-binding domains of Swi4 and Mbp1

• Perform sequential ChIP (re-ChIP) to identify co-binding of Swi6 with either Swi4 or Mbp1

• Analyze binding to SCB vs. MCB consensus sequences in promoters

• Compare binding patterns in single and double mutants (swi4Δ, mbp1Δ, swi4Δ mbp1Δ)

Key insight: Despite distinct DNA-binding preferences (Swi4 prefers CLN2 promoter while Mbp1 prefers RNR1 promoter), there is functional overlap between SBF and MBF in regulating many G1/S genes, which cannot be explained solely by promoter sequence analysis .

What methodological approaches can resolve apparent contradictions in SWI4 binding data?

Contradictions in SWI4 binding data often stem from methodological differences:

Resolution strategies:

• Compare ChIP-seq with in vivo footprinting for the same promoters

• Consider the influence of Swi6 on Swi4 DNA binding capacity

• Account for auto-inhibition of Swi4 DNA binding by its C-terminus

• Use quantitative microscopy (scanning number and brightness) to measure absolute protein concentrations

Research insight: The DNA binding domain of Swi4 is inaccessible in the full-length protein when not complexed with Swi6, which explains contradictions between in vitro binding capacity of overexpressed Swi4 fragments versus in vivo binding of endogenous full-length protein .

How can I study the auto-regulatory properties of SWI4 expression?

SWI4 auto-regulation can be studied through multiple approaches:

Experimental strategies:

• Mutate SBF binding sites in the SWI4 promoter and measure effects on:

  • SWI4 protein accumulation rate (molecules/fL)

  • Expression timing during cell cycle

  • Cell size at Start

• Use inducible SWI4 expression systems:

  • Z3EV-responsive promoter with beta-estradiol induction

  • Measure endogenous SWI4-GFP levels following ectopic SWI4 induction

Research findings: Ectopic induction of untagged SWI4 increases production of SWI4-GFP from the endogenous promoter, accelerates the G1/S transition, and upregulates other G1/S genes, supporting the auto-regulatory model .

What techniques can quantify absolute SWI4 protein abundance in single cells?

Absolute quantification of SWI4 in single cells uses advanced microscopy approaches:

Recommended technique: Scanning Number and Brightness (sN&B) particle counting

• Labels SWI4 with fast-folding monomeric GFP (mGFPmut3)

• Measures fluorescence intensity fluctuations to determine molecular brightness

• Calculates nuclear concentration and estimates nuclear volume

• Computes absolute protein copy number per cell

Technical considerations:

• Account for nuclear volume scaling with cell size

• Consider potential impacts of GFP tag on protein stability or function

• Calibrate using known standards

• Image in conditions that minimize photobleaching

This approach revealed that wild-type cells contain approximately 170±20 SWI4 molecules at Start, providing a quantitative framework for understanding SWI4 function .

How can SWI4 antibodies be used to study DNA damage responses?

SWI4 is implicated in genome stability, making it relevant for DNA damage studies:

Applications:

• ChIP to monitor SWI4 binding to damage-responsive genes

• Immunofluorescence to track SWI4 localization after genotoxic stress

• Co-IP to identify damage-specific interaction partners

Research findings: Cells lacking SWI6 (the SWI4 partner in SBF) display increased sensitivity to genotoxic agents, higher levels of DNA damage, and ineffective repair. These phenotypes correlate with changes in SWI4 and RAD51 transcription .

This suggests SWI4 antibody applications in studying how G1/S regulation interfaces with genome maintenance pathways .

What are the recommended controls for SWI4 ChIP experiments investigating genotoxic stress responses?

ChIP experiments investigating SWI4 under genotoxic stress require specific controls:

Essential controls:

• Input DNA sample before immunoprecipitation

• Non-specific IgG immunoprecipitation

• Positive control regions (known SWI4 targets like CLN1/CLN2)

• Negative control regions (e.g., gene-free region on chromosome I)

• ChIP in wild-type vs. swi4Δ strains

• ChIP in treated vs. untreated conditions with matched time points

Normalization approach: When studying genotoxic stress, normalize H3 ChIP signals to gene-free reference regions (e.g., IGR-I), and normalize SWI4-V5 ChIP to constitutive binding sites (e.g., CLN1/CLN2) .

Research has shown that genotoxic stress can alter SWI4 binding patterns, requiring careful experimental design and controls to distinguish direct from indirect effects .

How can LUTI-based regulation of SWI4 be experimentally distinguished from canonical transcriptional regulation?

LUTI (Long Undecoded Transcript Isoform) regulation represents an important mechanism for controlling SWI4:

Experimental approaches:

• RNA blotting to visualize different SWI4 mRNA isoforms

• Delete the LUTI promoter (ΔLUTI) and measure effects on:

  • SWI4 mRNA levels

  • SWI4 protein abundance

  • Timing of meiotic entry

• Mutate upstream ORFs (uORFs) in the LUTI 5' leader sequence

• Use single-molecule FISH (smFISH) to visualize different SWI4 transcript isoforms

Research findings: During meiosis, SWI4 LUTI expression leads to decreased canonical SWI4 transcript and protein levels. Mutation of the seven uORFs within SWI4 LUTI increases SWI4 protein levels, confirming the translational regulation component .

What methods can detect Swi4-Swi6 complex formation versus free Swi4?

Distinguishing between complexed and uncomplexed SWI4 is crucial for understanding its function:

Recommended techniques:

• Co-immunoprecipitation with antibodies to both Swi4 and Swi6

• Size exclusion chromatography to separate monomeric from complexed Swi4

• Sucrose gradient centrifugation

• FRET-based assays using fluorescent protein-tagged Swi4 and Swi6

• In vitro binding assays with recombinant proteins

Key research insight: Full-length Swi4 is monomeric in solution and cannot bind SCBs in the absence of Swi6, while C-terminal truncations or mutations can bind DNA independently. This suggests an intramolecular auto-inhibition mechanism that is relieved by Swi6 binding .

How can antibody-based approaches help study the antagonistic relationship between Swi4 and Ime1 during meiotic entry?

Recent research has revealed antagonism between Swi4 and Ime1 during meiotic fate decisions:

Methodological approaches:

• Dual immunofluorescence using antibodies against both transcription factors

• Quantitative measurement of nuclear localization using DAPI as a nuclear marker

• Single-cell analysis of protein levels and localization patterns

• ChIP-seq to identify competitive binding sites

Research findings: Higher nuclear Swi4 levels correlate with reduced nuclear Ime1, showing an inverse relationship. In wild-type cells entering meiosis, nuclear Swi4 decreases while Ime1 increases, but SWI4 overexpression disrupts this pattern and interferes with the meiotic transcriptional program .

This research demonstrates how antibody-based single-cell imaging can reveal regulatory antagonism between transcription factors during cell fate decisions .

What approaches can resolve differences between in vitro and in vivo SWI4 DNA binding activity?

Resolving differences between in vitro and in vivo binding requires specialized approaches:

Methodological strategies:

• Use purified recombinant Swi4 fragments versus full-length protein

• Test DNA binding with and without Swi6

• Examine the effect of mutations in the C-terminal region of Swi4

• Perform in vivo footprinting to detect protected regions

• Use cross-species complementation to assess functional conservation

Research insight: The DNA binding domain of Swi4 is inaccessible in the full-length protein when not complexed with Swi6. The C-terminus of Swi4 physically prevents the DNA binding domain from binding SCBs, and this inhibition is relieved by interaction with Swi6 .

This explains why overexpression of C-terminal truncations of Swi4 can promote Swi6-independent transcription while endogenous levels of full-length Swi4 cannot activate SCB reporter genes in the absence of Swi6 .